Literature DB >> 34286681

Effects of Patient Characteristics on Diagnostic Performance of Self-Collected Samples for SARS-CoV-2 Testing.

Sarah E Smith-Jeffcoat, Mitsuki Koh, Adam Hoffman, Paulina A Rebolledo, Marcos C Schechter, Halie K Miller, Sadia Sleweon, Rebecca Rossetti, Vyjayanti Kasinathan, Talya Shragai, Kevin O'Laughlin, Catherine C Espinosa, George M Khalil, AdeSubomi O Adeyemo, Anne Moorman, Brenda L Bauman, Kahaliah Joseph, Michelle O'Hegarty, Nazia Kamal, Hany Atallah, Brooks L Moore, Caitlin D Bohannon, Bettina Bankamp, Claire Hartloge, Michael D Bowen, Ashley Paulick, Amy S Gargis, Christopher Elkins, Rebekah J Stewart, Juliana da Silva, Caitlin Biedron, Jacqueline E Tate, Yun F Wang, Hannah L Kirking.   

Abstract

We evaluated the performance of self-collected anterior nasal swab (ANS) and saliva samples compared with healthcare worker-collected nasopharyngeal swab specimens used to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the same PCR diagnostic panel to test all self-collected and healthcare worker-collected samples from participants at a public hospital in Atlanta, Georgia, USA. Among 1,076 participants, 51.9% were men, 57.1% were >50 years of age, 81.2% were Black (non-Hispanic), and 74.9% reported >1 chronic medical condition. In total, 8.0% tested positive for SARS-CoV-2. Compared with nasopharyngeal swab samples, ANS samples had a sensitivity of 59% and saliva samples a sensitivity of 68%. Among participants tested 3-7 days after symptom onset, ANS samples had a sensitivity of 80% and saliva samples a sensitivity of 85%. Sensitivity varied by specimen type and patient characteristics. These findings can help physicians interpret PCR results for SARS-CoV-2.

Entities:  

Keywords:  2019 novel coronavirus disease; COVID-19; Georgia; SARS-CoV-2; United States; anterior nasal; coronavirus disease; coronaviruses; respiratory infections; saliva; self-collected; sensitivity; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Year:  2021        PMID: 34286681     DOI: 10.3201/eid2708.210667

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


  4 in total

Review 1.  Saliva as a diagnostic specimen for SARS-CoV-2 detection: A scoping review.

Authors:  Yifei Wang; Akshaya Upadhyay; Sangeeth Pillai; Parisa Khayambashi; Simon D Tran
Journal:  Oral Dis       Date:  2022-04-21       Impact factor: 4.068

2.  Risk-Factors for Exposure Associated With SARS-CoV-2 Detection After Recent Known or Potential COVID-19 Exposures Among Patients Seeking Medical Care at a Large Urban, Public Hospital in Fulton County, Georgia - A Cross-Sectional Investigation.

Authors:  Sarah E Smith-Jeffcoat; Sadia Sleweon; Mitsuki Koh; George M Khalil; Marcos C Schechter; Paulina A Rebolledo; Vyjayanti Kasinathan; Adam Hoffman; Rebecca Rossetti; Talya Shragai; Kevin O'Laughlin; Catherine C Espinosa; Bettina Bankamp; Michael D Bowen; Ashley Paulick; Amy S Gargis; Jennifer M Folster; Juliana da Silva; Caitlin Biedron; Rebekah J Stewart; Yun F Wang; Hannah L Kirking; Jacqueline E Tate
Journal:  Front Public Health       Date:  2022-03-24

3.  Update of Guidelines for Laboratory Diagnosis of COVID-19 in Korea.

Authors:  Ki Ho Hong; Gab Jung Kim; Kyoung Ho Roh; Heungsup Sung; Jaehyeon Lee; So Yeon Kim; Taek Soo Kim; Jae-Sun Park; Hee Jae Huh; Younhee Park; Jae-Seok Kim; Hyun Soo Kim; Moon-Woo Seong; Nam Hee Ryoo; Sang Hoon Song; Hyukmin Lee; Gye Cheol Kwon; Cheon Kwon Yoo
Journal:  Ann Lab Med       Date:  2022-07-01       Impact factor: 4.941

4.  Specimen self-collection for SARS-CoV-2 testing: Patient performance and preferences-Atlanta, Georgia, August-October 2020.

Authors:  Kevin O'Laughlin; Catherine C Espinosa; Sarah E Smith-Jeffcoat; Mitsuki Koh; George M Khalil; Adam Hoffman; Paulina A Rebolledo; Marcos C Schechter; Rebekah J Stewart; Juliana da Silva; Caitlin Biedron; Bettina Bankamp; Jennifer Folster; Amy S Gargis; Michael D Bowen; Ashley Paulick; Yun F Wang; Jacqueline E Tate; Hannah L Kirking
Journal:  PLoS One       Date:  2022-03-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.